Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 8:57 p.m.

    📋 Ideaya Biosciences Inc (IDYA) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 06:11:07

    Event Type: Clinical Trial Update

    Event Details:

    Ideaya Biosciences Inc (IDYA) Announces Clinical Trial Update Ideaya Biosciences Inc (IDYA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Collaboration: IRS Employer Identification Number
      • targeting CDKN2A, the most common co-alteration of MTAP, by the end of 2026
      • expected in Q1 ’26 • Randomized PFS analysis is based on the first 130 PFS events from the intent-to-treat population enrolled in the Phase 2b/3 portion of the trial, which comprises approximately 313 patients randomized 2:1 to the treatment versus control arm. The topline PFS results, if positive, are anticipated to enable a potential accelerated approval filing in the United States • Darovasertib is anticipated to be in three randomized, Phase 3 registrational trials across all stages of uveal melanoma by H1 ’26 • OptimUM-02 (mUM): full enrollment of 437 patients complete as of December 2025

    🔬 Clinical Development Pipeline (Ideaya Biosciences Inc):

    Product Type Development Stage Therapeutic Area Source
    IDE892 DRUG Phase PHASE1 NSCLC Adenocarcinoma ClinicalTrials.gov
    Crizotinib DRUG Phase PHASE1 Metastatic Uveal Melanoma ClinicalTrials.gov
    IDE161 DRUG Phase PHASE1 Small-cell Lung Cancer ClinicalTrials.gov
    IDE849 DRUG Phase PHASE1 Small-cell Lung Cancer ClinicalTrials.gov
    Darovasertib DRUG Phase PHASE2 Uveal Melanoma ClinicalTrials.gov
    IDE397 DRUG Phase PHASE1 NSCLC Adenocarcinoma ClinicalTrials.gov
    Binimetinib DRUG Phase PHASE1 Metastatic Uveal Melanoma ClinicalTrials.gov
    IDE196 DRUG Phase PHASE1 Metastatic Uveal Melanoma ClinicalTrials.gov
    Pembrolizumab DRUG Phase PHASE1 Advanced or Metastatic Solid Tumors ClinicalTrials.gov
    IDE-161 DRUG Phase PHASE1 Advanced or Metastatic Solid Tumors ClinicalTrials.gov
    durvalumab DRUG Phase PHASE1 Small-cell Lung Cancer ClinicalTrials.gov
    Sacituzumab govitecan DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    Paclitaxel DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    Docetaxel DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    Dacarbazine DRUG Phase PHASE2 Metastatic Uveal Melanoma ClinicalTrials.gov
    Nivolumab DRUG Phase PHASE2 Metastatic Uveal Melanoma ClinicalTrials.gov
    Ipilimumab DRUG Phase PHASE2 Metastatic Uveal Melanoma ClinicalTrials.gov
    Primary Local Therapy PROCEDURE Phase PHASE3 Uveal Melanoma ClinicalTrials.gov
    AP601 DRUG Phase PHASE1 Solid Tumours ClinicalTrials.gov
    doxecitine and doxribtimine DRUG Phase PHASE2 Thymidine Kinase 2 Deficiency ClinicalTrials.gov
    fenfluramine DRUG Phase PHASE3 Dravet Syndrome ClinicalTrials.gov
    AP505 DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    PD-1 inhibitor BIOLOGICAL Phase PHASE1 Neoplasms, Colorectal ClinicalTrials.gov
    GSK4418959 DRUG Phase PHASE1 Neoplasms, Colorectal ClinicalTrials.gov
    fenfluramine HCl DRUG Phase PHASE1 Healthy Study Participants ClinicalTrials.gov
    bupropion DRUG Phase PHASE1 Healthy Study Participants ClinicalTrials.gov
    metformin DRUG Phase PHASE1 Healthy Study Participants ClinicalTrials.gov
    midazolam DRUG Phase PHASE1 Healthy Study Participants ClinicalTrials.gov
    AP203 DRUG Phase PHASE1 Locally Advanced or Metastatic Solid Tumors ClinicalTrials.gov
    AP402 (Part 2 Dose Expansion) DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    AP402 (Part 1 Dose esclation) DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Ideaya Biosciences Inc
    • Ticker Symbol: IDYA

Search

News categories